We recently compiled a list of the 35 Trending AI Stocks on Latest News and Analyst Ratings. In this article, we are going to take a look at where Exscientia plc (NASDAQ:EXAI) stands against the other ...

AI-focused drug discovery firms Recursion (NASDAQ:RXRX) and Exscientia (NASDAQ:EXAI) on Thursday solicited shareholder support for their proposed merger agreement at upcoming investor meetings next ...

Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (EXAI) have each received overwhelming approval from their shareholders for the proposed ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Exscientia Plc (EXAI) has released an update. Don't Miss our Black Friday Offers: Exscientia Plc merges with Recursion to form a powerful AI-driven drug discovery platform, marking a significant step ...

Recursion (RXRX) and Exscientia plc (EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia. The transaction is expected ...

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...